Nanomaterials in tumor immunotherapy: new strategies and challenges

Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality of anti-tumor therapy with significant clinical efficacy and advantages compared to chemotherapy, radiotherapy and targeted therapy. Although various...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer Vol. 22; no. 1; pp. 94 - 28
Main Authors Zhu, Xudong, Li, Shenglong
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 13.06.2023
BioMed Central
BMC
Subjects
Antibodies
Antigens
Biocompatibility
Cancer
Cancer therapies
Chemotherapy
Comparative analysis
Cytokines
Drug delivery
Drug therapy
Drugs
Efficiency
Hydrogel nanoparticles
Hydrogels
Immune response
Immune system
Immunosuppressive agents
Immunotherapy
Lipid nanoparticles
Liposomes
Lymphocytes
Medical research
Metastasis
Nanomaterials
Nanoparticles
Nanotechnology
Permeability
Poly lactic-co-glycolic acid
Polymers
Radiation therapy
Review
T cell receptors
Tumor immunotherapy
Tumors
Nanoemulsions
Nanomaterials
Poly lactic-co-glycolic acid
Tumor immunotherapy
Liposomes
Hydrogel nanoparticles
Lipid nanoparticles
Online AccessGet full text

Cover

Abstract Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality of anti-tumor therapy with significant clinical efficacy and advantages compared to chemotherapy, radiotherapy and targeted therapy. Although various kinds of tumor immunotherapeutic drugs have emerged, the challenges faced in the delivery of these drugs, such as poor tumor permeability and low tumor cell uptake rate, had prevented their widespread application. Recently, nanomaterials had emerged as a means for treatment of different diseases due to their targeting properties, biocompatibility and functionalities. Moreover, nanomaterials possess various characteristics that overcome the defects of traditional tumor immunotherapy, such as large drug loading capacity, precise tumor targeting and easy modification, thus leading to their wide application in tumor immunotherapy. There are two main classes of novel nanoparticles mentioned in this review: organic (polymeric nanomaterials, liposomes and lipid nanoparticles) and inorganic (non-metallic nanomaterials and metallic nanomaterials). Besides, the fabrication method for nanoparticles, Nanoemulsions, was also introduced. In summary, this review article mainly discussed the research progress of tumor immunotherapy based on nanomaterials in the past few years and offers a theoretical basis for exploring novel tumor immunotherapy strategies in the future.
AbstractList Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality of anti-tumor therapy with significant clinical efficacy and advantages compared to chemotherapy, radiotherapy and targeted therapy. Although various kinds of tumor immunotherapeutic drugs have emerged, the challenges faced in the delivery of these drugs, such as poor tumor permeability and low tumor cell uptake rate, had prevented their widespread application. Recently, nanomaterials had emerged as a means for treatment of different diseases due to their targeting properties, biocompatibility and functionalities. Moreover, nanomaterials possess various characteristics that overcome the defects of traditional tumor immunotherapy, such as large drug loading capacity, precise tumor targeting and easy modification, thus leading to their wide application in tumor immunotherapy. There are two main classes of novel nanoparticles mentioned in this review: organic (polymeric nanomaterials, liposomes and lipid nanoparticles) and inorganic (non-metallic nanomaterials and metallic nanomaterials). Besides, the fabrication method for nanoparticles, Nanoemulsions, was also introduced. In summary, this review article mainly discussed the research progress of tumor immunotherapy based on nanomaterials in the past few years and offers a theoretical basis for exploring novel tumor immunotherapy strategies in the future.
Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality of anti-tumor therapy with significant clinical efficacy and advantages compared to chemotherapy, radiotherapy and targeted therapy. Although various kinds of tumor immunotherapeutic drugs have emerged, the challenges faced in the delivery of these drugs, such as poor tumor permeability and low tumor cell uptake rate, had prevented their widespread application. Recently, nanomaterials had emerged as a means for treatment of different diseases due to their targeting properties, biocompatibility and functionalities. Moreover, nanomaterials possess various characteristics that overcome the defects of traditional tumor immunotherapy, such as large drug loading capacity, precise tumor targeting and easy modification, thus leading to their wide application in tumor immunotherapy. There are two main classes of novel nanoparticles mentioned in this review: organic (polymeric nanomaterials, liposomes and lipid nanoparticles) and inorganic (non-metallic nanomaterials and metallic nanomaterials). Besides, the fabrication method for nanoparticles, Nanoemulsions, was also introduced. In summary, this review article mainly discussed the research progress of tumor immunotherapy based on nanomaterials in the past few years and offers a theoretical basis for exploring novel tumor immunotherapy strategies in the future.Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality of anti-tumor therapy with significant clinical efficacy and advantages compared to chemotherapy, radiotherapy and targeted therapy. Although various kinds of tumor immunotherapeutic drugs have emerged, the challenges faced in the delivery of these drugs, such as poor tumor permeability and low tumor cell uptake rate, had prevented their widespread application. Recently, nanomaterials had emerged as a means for treatment of different diseases due to their targeting properties, biocompatibility and functionalities. Moreover, nanomaterials possess various characteristics that overcome the defects of traditional tumor immunotherapy, such as large drug loading capacity, precise tumor targeting and easy modification, thus leading to their wide application in tumor immunotherapy. There are two main classes of novel nanoparticles mentioned in this review: organic (polymeric nanomaterials, liposomes and lipid nanoparticles) and inorganic (non-metallic nanomaterials and metallic nanomaterials). Besides, the fabrication method for nanoparticles, Nanoemulsions, was also introduced. In summary, this review article mainly discussed the research progress of tumor immunotherapy based on nanomaterials in the past few years and offers a theoretical basis for exploring novel tumor immunotherapy strategies in the future.
Abstract Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality of anti-tumor therapy with significant clinical efficacy and advantages compared to chemotherapy, radiotherapy and targeted therapy. Although various kinds of tumor immunotherapeutic drugs have emerged, the challenges faced in the delivery of these drugs, such as poor tumor permeability and low tumor cell uptake rate, had prevented their widespread application. Recently, nanomaterials had emerged as a means for treatment of different diseases due to their targeting properties, biocompatibility and functionalities. Moreover, nanomaterials possess various characteristics that overcome the defects of traditional tumor immunotherapy, such as large drug loading capacity, precise tumor targeting and easy modification, thus leading to their wide application in tumor immunotherapy. There are two main classes of novel nanoparticles mentioned in this review: organic (polymeric nanomaterials, liposomes and lipid nanoparticles) and inorganic (non-metallic nanomaterials and metallic nanomaterials). Besides, the fabrication method for nanoparticles, Nanoemulsions, was also introduced. In summary, this review article mainly discussed the research progress of tumor immunotherapy based on nanomaterials in the past few years and offers a theoretical basis for exploring novel tumor immunotherapy strategies in the future.
Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality of anti-tumor therapy with significant clinical efficacy and advantages compared to chemotherapy, radiotherapy and targeted therapy. Although various kinds of tumor immunotherapeutic drugs have emerged, the challenges faced in the delivery of these drugs, such as poor tumor permeability and low tumor cell uptake rate, had prevented their widespread application. Recently, nanomaterials had emerged as a means for treatment of different diseases due to their targeting properties, biocompatibility and functionalities. Moreover, nanomaterials possess various characteristics that overcome the defects of traditional tumor immunotherapy, such as large drug loading capacity, precise tumor targeting and easy modification, thus leading to their wide application in tumor immunotherapy. There are two main classes of novel nanoparticles mentioned in this review: organic (polymeric nanomaterials, liposomes and lipid nanoparticles) and inorganic (non-metallic nanomaterials and metallic nanomaterials). Besides, the fabrication method for nanoparticles, Nanoemulsions, was also introduced. In summary, this review article mainly discussed the research progress of tumor immunotherapy based on nanomaterials in the past few years and offers a theoretical basis for exploring novel tumor immunotherapy strategies in the future. Keywords: Nanomaterials, Tumor immunotherapy, Poly lactic-co-glycolic acid, Hydrogel nanoparticles, Liposomes, Lipid nanoparticles, Nanoemulsions
ArticleNumber 94
Audience Academic
Author Zhu, Xudong
Li, Shenglong
Author_xml – sequence: 1
  givenname: Xudong
  surname: Zhu
  fullname: Zhu, Xudong
– sequence: 2
  givenname: Shenglong
  surname: Li
  fullname: Li, Shenglong
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37312116$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1DAUhSNURB_wB1igSGzYpPgRv9igatRCpQo2sLYc53rGo8Qe7ATUf4_TaaFTIRxZjpzvnOhcndPqKMQAVfUao3OMJX-fMVEtbRApGwslGvWsOsGt4E3LlDx69H5cnea8RYWSon1RHVNBMcGYn1SrLybE0UyQvBly7UM9zWNMtR_HOcRpA8nsbj_UAX7VeUqFW3vItQl9bTdmGCCsIb-snrsihlf351n1_ery2-pzc_P10_Xq4qaxjLdTg3tgpscG9Z1lVDpOALrOAuGCS8kNQpYLsAyYAyqEcJT1jFuqmOLYuY6eVdd73z6ard4lP5p0q6Px-u4iprU2afJ2AG0owsi1WHbGtb1pZcsx6jBYUFSVMRSvj3uv3dyN0FsIJd1wYHr4JfiNXsefGiPCCaOsOLy7d0jxxwx50qPPFobBBIhz1kQSJpESRBb07RN0G-cUyqwWSuCyWvSXWpuSwAcXy4_tYqovBCOKcsUW6vwfVHl6GL0tBXG-3B8I3jxO-ifiQwcKIPeATTHnBE5bP5nJxyW4H0pivdRN7-umS930Xd20KlLyRPrg_h_Rb2hd1hc
CitedBy_id crossref_primary_10_1016_j_actbio_2024_08_055
crossref_primary_10_5802_crchim_348
crossref_primary_10_1039_D4RA07193J
crossref_primary_10_1039_D3FO05441A
crossref_primary_10_1016_j_ijbiomac_2023_128504
crossref_primary_10_1016_j_ijpharm_2025_125287
crossref_primary_10_1039_D4NR00243A
crossref_primary_10_1186_s12951_024_03068_1
crossref_primary_10_2147_IJN_S455213
crossref_primary_10_1002_advs_202306305
crossref_primary_10_1007_s10565_024_09943_9
crossref_primary_10_1186_s12951_024_02785_x
crossref_primary_10_3390_ijms25115632
crossref_primary_10_3390_nano14090797
crossref_primary_10_1186_s12935_024_03216_5
crossref_primary_10_1002_adtp_202400160
crossref_primary_10_3389_fbioe_2023_1266888
crossref_primary_10_1016_j_isci_2024_109350
crossref_primary_10_1016_j_jcis_2024_07_172
crossref_primary_10_3389_fimmu_2025_1525052
crossref_primary_10_1016_j_actbio_2024_07_042
crossref_primary_10_1021_acsami_4c05714
crossref_primary_10_1002_adhm_202402967
crossref_primary_10_1088_1361_6528_ad170b
crossref_primary_10_1021_acsabm_4c01797
crossref_primary_10_2147_IJN_S442446
crossref_primary_10_3389_fimmu_2023_1228486
crossref_primary_10_2147_IJN_S470478
crossref_primary_10_1002_anie_202423446
crossref_primary_10_1002_smll_202311702
crossref_primary_10_1016_j_ijpharm_2025_125336
crossref_primary_10_1016_j_pmatsci_2024_101375
crossref_primary_10_1038_s41420_024_02146_5
crossref_primary_10_1016_j_intimp_2024_113085
crossref_primary_10_1016_j_apsb_2023_11_032
crossref_primary_10_1016_j_ijpharm_2024_124956
crossref_primary_10_1016_j_nantod_2025_102714
crossref_primary_10_1002_mog2_70000
crossref_primary_10_1038_s41541_024_00807_1
crossref_primary_10_1080_23723556_2024_2423986
crossref_primary_10_3390_ph17070932
crossref_primary_10_1038_s41598_023_50878_8
crossref_primary_10_34133_bmr_0146
crossref_primary_10_1126_sciadv_adn8695
crossref_primary_10_2147_IJN_S456632
crossref_primary_10_1002_cbf_4098
crossref_primary_10_1016_j_matdes_2024_112893
crossref_primary_10_1021_acsnano_4c09190
crossref_primary_10_1016_j_jcis_2024_08_118
crossref_primary_10_1016_j_biopha_2024_117553
crossref_primary_10_1002_ange_202423446
crossref_primary_10_1007_s10495_023_01922_5
crossref_primary_10_2147_IJN_S505539
crossref_primary_10_1016_j_cej_2024_150356
crossref_primary_10_1016_j_ijpharm_2025_125224
crossref_primary_10_1186_s40001_024_01699_6
crossref_primary_10_3390_cancers16112030
crossref_primary_10_1002_adhm_202402697
crossref_primary_10_1016_j_arabjc_2023_105352
crossref_primary_10_1016_j_ijbiomac_2024_139147
crossref_primary_10_3389_fimmu_2025_1562766
crossref_primary_10_1007_s11302_025_10071_0
crossref_primary_10_3390_pharmaceutics17040409
crossref_primary_10_3390_gels11030152
crossref_primary_10_3389_fimmu_2025_1496498
crossref_primary_10_3390_ijms26062633
crossref_primary_10_1002_adfm_202502646
crossref_primary_10_1016_j_lfs_2024_122897
crossref_primary_10_1021_acs_molpharmaceut_3c00846
crossref_primary_10_1002_cnr2_70063
crossref_primary_10_1208_s12249_024_02883_x
crossref_primary_10_1021_acs_chemmater_3c03338
crossref_primary_10_1097_JS9_0000000000002224
crossref_primary_10_2147_IJN_S504318
crossref_primary_10_1016_j_isci_2024_111597
crossref_primary_10_1016_j_nantod_2024_102311
crossref_primary_10_1021_acs_nanolett_5c00677
crossref_primary_10_1002_smll_202400654
crossref_primary_10_1007_s10495_024_01995_w
crossref_primary_10_1016_j_cej_2024_157580
crossref_primary_10_3389_fimmu_2024_1441410
crossref_primary_10_1080_15384047_2024_2343450
crossref_primary_10_1186_s12951_024_02614_1
crossref_primary_10_1080_1061186X_2024_2367579
crossref_primary_10_26599_NBE_2024_9290100
crossref_primary_10_1016_j_ijpharm_2024_125106
crossref_primary_10_1021_acsnano_4c02265
crossref_primary_10_1021_acsami_4c13445
crossref_primary_10_1039_D4TB00084F
crossref_primary_10_1016_j_jcis_2024_03_186
crossref_primary_10_1016_j_ajps_2024_100993
crossref_primary_10_1016_j_heliyon_2024_e34951
Cites_doi 10.1021/acsnano.8b05893
10.1039/D0TB02737E
10.1186/s13045-022-01305-4
10.1016/j.it.2022.08.004
10.1016/j.jconrel.2022.03.021
10.1016/j.biomaterials.2020.120469
10.1038/s41565-020-00822-y
10.1038/s41571-021-00532-x
10.1021/acs.nanolett.1c03004
10.1038/s41388-021-02132-6
10.1080/10717544.2021.1943056
10.3390/ijms22020843
10.1186/s13045-022-01322-3
10.3389/fimmu.2019.00172
10.1080/10717544.2020.1809559
10.1016/j.biomaterials.2010.05.027
10.3390/nano12172948
10.1039/d2tb00387b
10.3389/fimmu.2018.02076
10.1038/s41573-018-0007-y
10.1038/ni.2035
10.1021/acsbiomaterials.0c00883
10.2174/1389450122666210906121803
10.3390/nano12050836
10.1186/s13045-021-01096-0
10.2147/IJN.S242463
10.1016/j.trecan.2022.04.004
10.1016/j.jconrel.2022.01.049
10.1126/science.aar7112
10.1021/acsami.0c09484
10.1016/j.jconrel.2022.06.012
10.1016/j.prp.2020.152954
10.1016/j.addr.2008.08.002
10.1016/j.addr.2022.114395
10.1016/j.semcancer.2022.08.004
10.1016/j.actbio.2018.04.006
10.1200/JCO.21.01497
10.1016/j.intimp.2021.107683
10.3109/08830185.2014.969421
10.1021/acsnano.7b08148
10.3389/fonc.2022.931995
10.1039/C8CS00896E
10.3390/nano12142337
10.1016/j.lfs.2020.117394
10.1007/s00262-022-03260-y
10.3390/cancers12010213
10.1002/adma.202103936
10.1186/s12964-022-00904-5
10.1080/14728222.2021.1937123
10.1039/D1TB00559F
10.1016/j.ejpb.2017.03.013
10.1016/j.actbio.2022.04.001
10.1186/s12929-022-00837-8
10.7150/thno.37198
10.1208/s12248-019-0333-y
10.1021/acs.nanolett.6b03329
10.1021/acsami.0c16728
10.1038/onc.2016.367
10.1016/j.intimp.2021.107532
10.1038/s41423-020-0488-6
10.1016/j.addr.2022.114503
10.4155/tde-2016-0006
10.1016/j.biomaterials.2021.121339
10.1002/adma.202002085
10.1186/s13054-017-1678-1
10.1016/j.addr.2020.06.002
10.3390/pharmaceutics14061127
10.1056/NEJMoa1701830
10.1039/D1TB00256B
10.1021/acs.nanolett.2c01994
10.1016/j.bioactmat.2022.01.003
10.1172/JCI96791
10.1016/j.vaccine.2022.06.043
10.1039/C8CS00618K
10.3389/fmolb.2022.900344
10.1021/acs.nanolett.2c01863
10.1002/ijc.31717
10.1002/smll.202104773
10.1002/1097-4636(200102)54:2<162::AID-JBM2>3.0.CO;2-3
10.1208/s12248-021-00611-y
10.1111/1541-4337.12604
10.3390/cancers14163908
10.1016/j.jconrel.2016.11.015
10.1158/1078-0432.CCR-16-0933
10.1039/D2CS00106C
10.21037/cco.2018.05.05
10.7150/ntno.65544
10.3390/ijms22115801
10.1016/j.ejpb.2015.03.018
10.1016/j.ccell.2020.09.001
10.3389/fimmu.2022.923477
10.3390/biom11121850
10.1126/science.aan3706
10.1038/s41586-019-1730-1
10.1016/j.jconrel.2021.07.035
10.1007/s00262-022-03343-w
10.1016/j.addr.2020.07.002
10.1016/j.ctrv.2016.02.001
10.1021/acsnano.0c09681
10.1073/pnas.1411393111
10.1186/s11671-019-3032-9
10.1016/j.bbadis.2019.165540
10.1007/s00262-022-03209-1
10.1126/scitranslmed.3003689
10.2147/IJN.S301552
10.1080/10408398.2021.1879727
10.1056/NEJMoa1915745
10.3390/cells11121974
10.1126/science.aaf2807
10.1172/JCI97570
10.3390/molecules27175607
10.3389/fmolb.2020.587997
10.1021/acs.nanolett.1c04888
10.1158/2159-8290.CD-18-0065
10.1016/j.biomaterials.2020.120560
10.1101/cshperspect.a030338
10.1016/j.apsb.2022.02.023
10.7554/eLife.79895
10.1021/acsnano.6b08152
10.1016/bs.ircmb.2022.03.002
10.1016/j.trecan.2022.05.005
10.1517/17425247.2012.689284
10.1080/10408347.2020.1808442
10.1089/omi.2021.0025
10.1155/2022/3119375
10.1002/mabi.201700092
10.1021/acsnano.9b06111
10.1038/s12276-022-00784-2
10.1126/scitranslmed.abo3605
10.1038/s41578-021-00358-0
10.1146/annurev-immunol-110519-071134
10.1186/s12943-021-01489-2
10.1146/annurev-cellbio-120420-125117
10.1002/smll.202203466
10.1073/pnas.2207841119
10.7150/thno.49577
10.3390/nano10081608
10.1016/j.cytogfr.2022.07.006
10.1007/s10311-021-01216-9
10.1016/j.addr.2022.114415
10.1039/b820162p
10.1038/s41593-019-0370-y
10.1016/j.canlet.2022.215823
10.1016/j.biomaterials.2021.120964
10.1016/j.ccell.2021.07.007
10.1002/jcp.27782
10.1002/advs.202100712
10.1158/1078-0432.CCR-06-1546
10.1186/s13045-021-01056-8
10.1016/j.msec.2020.110698
10.1016/j.ijbiomac.2020.12.161
10.1038/s41571-022-00689-z
10.1038/s41467-020-18570-x
10.1039/D1BM01537K
10.1126/science.aae0491
10.1016/j.tips.2019.11.003
10.1056/NEJMoa1809615
10.1016/j.lfs.2022.120734
10.1021/acsnano.7b09041
10.1002/anie.202015590
10.1021/acsami.2c08619
10.1038/ni.3796
10.1007/s13197-021-05128-y
10.1016/j.jconrel.2022.01.034
10.3390/life11040269
10.7150/thno.46089
10.1016/j.actbio.2021.09.062
10.1016/j.biomaterials.2022.121677
10.1136/jitc-2020-000957
10.1080/10717544.2021.1938756
10.1016/j.phrs.2020.104902
10.1146/annurev-immunol-041015-055318
10.1002/wnan.1842
10.1002/med.21771
10.1016/j.jconrel.2021.05.040
10.3390/nano10020364
10.1038/s41590-022-01291-2
10.1186/s12951-022-01692-3
10.1186/s12951-022-01270-7
10.1186/s40580-022-00322-w
10.1056/NEJMoa1503093
10.1016/j.ctrv.2022.102461
10.1016/j.bioadv.2022.212725
10.3389/fonc.2022.930125
10.1136/jitc-2022-004863
10.1016/j.ctrv.2022.102433
10.1038/nri3862
10.3390/cancers14123021
10.7150/thno.65480
10.1126/science.aay5967
10.3892/etm.2020.9416
10.1038/s41571-018-0142-8
10.1016/j.jconrel.2022.03.043
10.1080/08820139.2019.1610889
10.1186/s13046-016-0444-6
10.3390/cancers12061475
10.1002/adma.202109178
10.1038/nri3634
10.1038/s41565-021-00962-9
10.1021/acs.accounts.1c00544
10.1016/j.jconrel.2022.09.012
10.3389/fchem.2022.973666
10.1126/scitranslmed.aan3311
10.1016/j.bioactmat.2020.08.016
10.1158/1535-7163.MCT-20-0591
10.3390/pharmaceutics14081630
10.1038/nbt.4181
10.1016/j.ijpharm.2021.120571
10.1038/s41392-020-0144-8
10.1021/acsnano.9b04207
10.4274/tjps.galenos.2019.48751
10.1016/j.jconrel.2013.05.037
10.1007/s00262-021-02892-w
10.1016/j.semcancer.2021.04.021
10.1021/acs.molpharmaceut.1c00448
10.1016/j.addr.2022.114524
10.1182/blood-2017-06-741033
10.1186/s13045-022-01335-y
10.1038/s41565-018-0319-4
10.1186/s13045-022-01340-1
10.1021/acsnano.9b10103
10.1016/j.jconrel.2020.07.008
10.7150/thno.42471
10.1016/j.ijpharm.2022.121845
10.3389/fimmu.2021.641703
10.5694/mja13.11182
10.1007/s12272-016-0782-0
10.7150/thno.72339
10.2147/IJN.S121881
10.1186/s13045-022-01325-0
10.1016/j.jconrel.2022.05.057
10.1038/s41417-021-00299-4
10.1038/s41467-020-18298-8
10.1158/1078-0432.CCR-16-3001
10.1158/2159-8290.CD-15-0944
10.3390/ijms19113564
10.3389/fimmu.2023.1012841
10.1038/s41577-019-0269-6
10.1586/14760584.2013.811208
10.1016/j.biomaterials.2020.120190
10.3389/fimmu.2019.00707
10.1002/1878-0261.12834
10.1002/adma.202203890
10.1038/s41578-021-00379-9
10.1016/j.trecan.2022.06.009
10.1038/s41392-021-00727-9
10.1186/s13045-021-01103-4
10.1186/s12951-021-01073-2
10.1016/j.addr.2007.04.007
10.1016/j.nano.2021.102415
10.3390/pharmaceutics14010196
10.3389/fimmu.2021.715234
10.1126/sciadv.abc9450
10.1016/j.ijpharm.2013.04.063
10.1080/17425247.2016.1182485
10.3390/cancers14163972
10.1038/s41590-021-01047-4
10.1021/acsnano.7b00078
10.1038/s41698-022-00272-w
10.1038/s41587-020-0651-8
10.3322/caac.21660
10.1016/j.bbcan.2022.188797
10.3390/ijms222413310
10.3390/ijms22168884
10.1038/s41467-017-01830-8
10.1016/j.drup.2021.100796
10.1038/s41568-021-00340-6
10.1186/s12943-021-01335-5
10.1053/j.gastro.2022.06.024
10.1016/j.msec.2015.08.006
10.1182/blood-2006-11-059246
10.1016/j.phrs.2022.106425
10.1158/1078-0432.CCR-18-1543
10.1016/j.addr.2017.04.010
10.1016/j.carbpol.2019.115128
10.1158/0008-5472.CAN-18-0306
10.1016/j.immuni.2019.03.012
10.1016/j.jphotobiol.2020.111808
10.1038/s41467-021-23244-3
10.1016/j.addr.2022.114444
10.1089/jir.2018.0019
10.1016/S1470-2045(16)30035-3
10.1002/adma.202105667
10.1155/2019/3046379
10.1038/nri.2017.131
10.1002/smll.202103868
10.1038/nbt.3104
10.1007/s10439-016-1583-9
10.1016/j.msec.2017.12.036
10.1158/0008-5472.CAN-15-3164
10.1039/D1TB02470A
10.1039/D2CC02759C
10.1038/nrclinonc.2016.58
10.3390/pharmaceutics12121165
10.1038/s41467-018-04607-9
10.1093/bjs/znaa123
10.1158/2326-6066.CIR-22-0266
10.1200/JCO.2014.59.1586
10.1016/j.ejpb.2016.08.012
10.2147/IJN.S236927
10.1016/j.immuni.2018.03.014
10.1038/nnano.2017.57
10.2147/IJN.S295565
10.1016/j.immuni.2021.04.004
10.1186/1479-5876-11-246
10.1093/annonc/mdx444
10.3389/fimmu.2022.979469
10.1080/2162402X.2018.1445949
10.1038/embor.2012.127
10.1016/j.colsurfb.2022.112737
10.1080/17425247.2022.2045944
10.1007/s00109-015-1376-x
10.1016/j.lfs.2020.118605
10.1021/acsami.1c16154
10.2147/IJN.S249252
10.3390/pharmaceutics14081620
10.1155/2022/9910049
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
NPM
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12943-023-01797-9
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
CrossRef

MEDLINE - Academic


PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-4598
EndPage 28
ExternalDocumentID oai_doaj_org_article_a3010f418baf4da484610b1ece939017
PMC10262535
A752936950
37312116
10_1186_s12943_023_01797_9
Genre Journal Article
Review
GroupedDBID ---
0R~
123
29M
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PZZ
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
NPM
PMFND
3V.
7TO
7XB
8FK
AZQEC
COVID
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c564t-1de5ad1a0dbc538f62eebbce2676886a00c67ec5e5fe3777f35d56c395961ffb3
IEDL.DBID M48
ISSN 1476-4598
IngestDate Wed Aug 27 01:27:45 EDT 2025
Thu Aug 21 18:37:44 EDT 2025
Mon Jul 21 09:58:49 EDT 2025
Fri Jul 25 04:13:14 EDT 2025
Tue Jun 17 21:48:01 EDT 2025
Tue Jun 10 20:41:27 EDT 2025
Thu Apr 03 07:04:39 EDT 2025
Tue Jul 01 01:01:21 EDT 2025
Thu Apr 24 23:07:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Nanoemulsions
Nanomaterials
Poly lactic-co-glycolic acid
Tumor immunotherapy
Liposomes
Hydrogel nanoparticles
Lipid nanoparticles
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-1de5ad1a0dbc538f62eebbce2676886a00c67ec5e5fe3777f35d56c395961ffb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12943-023-01797-9
PMID 37312116
PQID 2827111140
PQPubID 42702
PageCount 28
ParticipantIDs doaj_primary_oai_doaj_org_article_a3010f418baf4da484610b1ece939017
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10262535
proquest_miscellaneous_2825809728
proquest_journals_2827111140
gale_infotracmisc_A752936950
gale_infotracacademiconefile_A752936950
pubmed_primary_37312116
crossref_citationtrail_10_1186_s12943_023_01797_9
crossref_primary_10_1186_s12943_023_01797_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-06-13
PublicationDateYYYYMMDD 2023-06-13
PublicationDate_xml – month: 06
  year: 2023
  text: 2023-06-13
  day: 13
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Molecular cancer
PublicationTitleAlternate Mol Cancer
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References JC Dawson (1797_CR263) 2021; 21
L Zhu (1797_CR158) 2015; 34
L Luo (1797_CR291) 2021; 11
AK Das (1797_CR220) 2020; 19
1797_CR258
SB Stephan (1797_CR310) 2015; 33
1797_CR133
J Park (1797_CR303) 2019; 9
AJ Almeida (1797_CR202) 2007; 59
E Limagne (1797_CR43) 2016; 76
1797_CR250
H Harjunpaa (1797_CR76) 2018; 7
M Chen (1797_CR168) 2021; 17
Y Dong (1797_CR234) 2020; 15
RC Smith (1797_CR3) 2014; 200
Q Chen (1797_CR160) 2019; 14
Y Yang (1797_CR252) 2022; 22
S Li (1797_CR15) 2022; 188
R Nussinov (1797_CR8) 2021; 59
1797_CR55
Y Hua (1797_CR30) 2021; 97
JA Marin-Acevedo (1797_CR84) 2021; 14
L Gao (1797_CR108) 2022; 10
JS O'Donnell (1797_CR74) 2019; 16
S Grisaru-Tal (1797_CR59) 2022; 23
1797_CR147
S Yokoyama (1797_CR5) 2021; 108
Y Wang (1797_CR57) 2022; 15
SS Lee (1797_CR288) 2019; 2019
TT Smith (1797_CR318) 2017; 12
1797_CR266
X Hou (1797_CR94) 2018; 143
1797_CR265
GL Rodriguez-Acosta (1797_CR124) 2022; 23
S Musetti (1797_CR53) 2018; 12
M Hamidi (1797_CR119) 2008; 60
Y Cao (1797_CR171) 2022; 18
P Rafiei (1797_CR167) 2017; 12
P Gu (1797_CR111) 2019; 223
U Ruman (1797_CR298) 2020; 15
1797_CR40
Z Li (1797_CR145) 2016; 109
C Jia (1797_CR290) 2022; 18
1797_CR49
Y Wang (1797_CR248) 2019; 10
Y Yan (1797_CR62) 2022; 15
Z Hu (1797_CR204) 2018; 18
A Roy (1797_CR214) 2022; 19
Z Chen (1797_CR245) 2022; 20
1797_CR39
F Danhier (1797_CR302) 2016; 244
M Ikeda-Imafuku (1797_CR304) 2022; 345
Y Tabana (1797_CR80) 2021; 25
L Hou (1797_CR240) 2020; 14
1797_CR115
GH Nam (1797_CR165) 2018; 9
1797_CR233
R Sun (1797_CR42) 2021; 15
1797_CR232
X Hou (1797_CR196) 2021; 6
H Pan (1797_CR4) 2017; 377
C Fu (1797_CR173) 2020; 20
X Wang (1797_CR29) 2020; 5
Y Fujiwara (1797_CR56) 2022; 110
J Jiang (1797_CR156) 2019; 14
AW Lund (1797_CR60) 2022; 10
N Pandey (1797_CR65) 2022; 188
1797_CR35
XT Yu (1797_CR99) 2022; 135
SJ Blake (1797_CR73) 2016; 22
1797_CR128
1797_CR246
J Zhou (1797_CR24) 2019; 18
Y Zhu (1797_CR19) 2022; 15
Y Liu (1797_CR292) 2019; 48
1797_CR122
N Vasan (1797_CR10) 2019; 575
SE Lee (1797_CR150) 2022; 288
T Sugie (1797_CR269) 2018; 7
S Basu (1797_CR267) 2022; 78
JS Dolina (1797_CR36) 2021; 12
B Han (1797_CR93) 2022; 343
AR Garizo (1797_CR144) 2021; 337
B Reig-Vano (1797_CR170) 2021; 170
1797_CR23
C Horejs (1797_CR197) 2021; 6
1797_CR21
J Koerner (1797_CR137) 2019; 10
W Zhang (1797_CR169) 2021; 33
Y Zheng (1797_CR305) 2013; 172
D Ding (1797_CR299) 2021; 8
1797_CR17
AM Reichmuth (1797_CR195) 2016; 7
LA Emens (1797_CR272) 2018; 24
1797_CR18
X Ren (1797_CR268) 2021; 39
RJ King (1797_CR25) 2022; 41
1797_CR297
1797_CR175
S Satta (1797_CR178) 2022; 12
1797_CR294
T Fujiwara (1797_CR32) 2021; 20
W Gao (1797_CR120) 2016; 44
P Xu (1797_CR95) 2020; 15
1797_CR11
S Shah (1797_CR179) 2020; 154–155
L Spain (1797_CR283) 2016; 44
1797_CR12
MA Oberli (1797_CR205) 2017; 17
KC Conlon (1797_CR211) 2019; 39
T Yin (1797_CR143) 2022; 22
N Dumauthioz (1797_CR54) 2018; 9
1797_CR13
Q Zhou (1797_CR300) 2021; 18
1797_CR1
Y Li (1797_CR231) 2022; 189
Q Peng (1797_CR142) 2020; 11
CK Lee (1797_CR146) 2022; 6
S Hegde (1797_CR249) 2021; 54
1797_CR185
1797_CR6
1797_CR181
Y Su (1797_CR109) 2021; 28
KE Pauken (1797_CR69) 2016; 354
C Liu (1797_CR225) 2020; 14
R Ge (1797_CR66) 2022; 6
E Perez-Herrero (1797_CR264) 2015; 93
K Reinhard (1797_CR311) 2020; 367
TM Ho (1797_CR219) 2022; 62
Z Cheng (1797_CR289) 2021; 14
P Kumar (1797_CR151) 2015; 57
J Li (1797_CR188) 2021; 335
1797_CR154
M Reck (1797_CR281) 2022; 40
S Kitano (1797_CR316) 2006; 12
1797_CR153
MC Rodrigues (1797_CR230) 2020; 204
JY Lee (1797_CR235) 2020; 12
1797_CR274
C Boutros (1797_CR280) 2016; 13
N Gong (1797_CR107) 2021; 16
RS Finn (1797_CR273) 2020; 382
1797_CR270
Y Shi (1797_CR301) 2020; 10
R Feng (1797_CR260) 2021; 266
C Martín-Otal (1797_CR20) 2022; 370
FJ Hartmann (1797_CR251) 2021; 39
J Kwon (1797_CR98) 2022; 9
A Pavlick (1797_CR314) 2020; 8
MC Takenaka (1797_CR33) 2019; 22
EJ Wherry (1797_CR50) 2015; 15
Y Wang (1797_CR61) 2022; 15
SB Kwak (1797_CR16) 2022; 54
M Labet (1797_CR117) 2009; 38
R Kedmi (1797_CR203) 2010; 31
1797_CR286
1797_CR287
1797_CR284
Y Zhang (1797_CR227) 2021; 60
1797_CR285
1797_CR282
G Di Conza (1797_CR159) 2021; 22
X Zhang (1797_CR224) 2020; 216
A Maali (1797_CR276) 2023; 14
Z Li (1797_CR155) 2022; 34
Y Liu (1797_CR64) 2020; 41
Y Eygeris (1797_CR201) 2022; 55
D Zhu (1797_CR41) 2019; 1865
H Chen (1797_CR26) 2022; 163
Y Wang (1797_CR191) 2022; 17
Y Dölen (1797_CR134) 2021; 12
B Rowshanravan (1797_CR279) 2018; 131
C Gao (1797_CR193) 2022; 22
Y Li (1797_CR14) 2022; 58
L Yang (1797_CR238) 2021; 19
Z Liu (1797_CR125) 2012; 9
F Shen (1797_CR184) 2020; 255
J Gao (1797_CR58) 2022; 20
A Chow (1797_CR78) 2022; 19
Q Su (1797_CR187) 2021; 9
JY Cherng (1797_CR116) 2013; 450
H Jin (1797_CR164) 2018; 12
AE Pomeroy (1797_CR261) 2022; 8
Y Hua (1797_CR113) 2021; 28
MDA Paskeh (1797_CR48) 2022; 15
Y Wang (1797_CR114) 2021; 23
F Wang (1797_CR132) 2021; 95
LM McLane (1797_CR85) 2019; 37
M Ghalkhani (1797_CR257) 2022; 52
M Yi (1797_CR277) 2022; 21
M Amin (1797_CR176) 2022; 189
K Dzobo (1797_CR172) 2021; 25
L You (1797_CR161) 2021; 41
QV Le (1797_CR105) 2019; 21
V De Leo (1797_CR177) 2022; 218
S Kageyama (1797_CR315) 2013; 11
Y Zhang (1797_CR255) 2020; 6
J Galon (1797_CR83) 2019; 18
F Zhang (1797_CR309) 2018; 78
A Bharadwaz (1797_CR112) 2020; 110
M Hu (1797_CR186) 2021; 15
1797_CR198
1797_CR199
AK Kosmides (1797_CR308) 2017; 11
D Guimaraes (1797_CR180) 2021; 601
1797_CR192
X Zang (1797_CR104) 2017; 115
C Rao (1797_CR89) 2022; 9
Y Wang (1797_CR295) 2022; 344
S Salatin (1797_CR121) 2016; 39
D Zhao (1797_CR126) 2021; 6
Y Zeng (1797_CR256) 2021; 268
Y Zheng (1797_CR306) 2017; 11
JP Vasilakos (1797_CR139) 2013; 12
A Mantovani (1797_CR210) 2019; 50
M Fan (1797_CR259) 2020; 10
L Tang (1797_CR319) 2018; 36
Y Lu (1797_CR254) 2022; 12
JQ Liu (1797_CR208) 2022; 345
H Lan (1797_CR92) 2020; 27
JKU Ling (1797_CR213) 2022; 59
N Rath (1797_CR166) 2012; 13
B Zeng (1797_CR222) 2018; 128
PS Liu (1797_CR157) 2017; 18
N Tokumasa (1797_CR37) 2007; 110
SJ Blake (1797_CR75) 2016; 6
Y Gao (1797_CR22) 2022; 2022
Z Wang (1797_CR182) 2022; 348
P Nirale (1797_CR216) 2020; 245
S Qing (1797_CR242) 2020; 32
S Han (1797_CR149) 2022; 348
TJ Ashaolu (1797_CR215) 2021; 19
Z Yuan (1797_CR183) 2022; 187
1797_CR212
X Liu (1797_CR174) 2019; 9
YP Chen (1797_CR236) 2020; 12
ME Goebeler (1797_CR275) 2016; 34
1797_CR91
1797_CR90
CR Garcia (1797_CR217) 2022; 10
P Zhao (1797_CR237) 2021; 16
IY Kuo (1797_CR45) 2022; 29
CC Zebley (1797_CR81) 2022; 8
Y Liu (1797_CR241) 2021; 33
1797_CR97
S Iranpour (1797_CR129) 2016; 35
J Gan (1797_CR244) 2020; 326
MG Gouveia (1797_CR123) 2023; 52
1797_CR229
J Zhao (1797_CR163) 2022; 20
1797_CR106
X Xiong (1797_CR140) 2021; 21
1797_CR101
1797_CR221
L Qiao (1797_CR296) 2022; 10
W Sang (1797_CR102) 2019; 48
J Koerner (1797_CR136) 2021; 12
1797_CR82
1797_CR88
W Linhart (1797_CR118) 2001; 54
1797_CR87
E Swider (1797_CR127) 2018; 73
R Yang (1797_CR138) 2018; 12
S Zhou (1797_CR247) 2021; 13
DR Sen (1797_CR70) 2016; 354
J Koh (1797_CR228) 2021; 37
X Sun (1797_CR243) 2021; 16
D Schmid (1797_CR307) 2017; 8
1797_CR317
L Cheng (1797_CR189) 2021; 275
W Yuan (1797_CR31) 2022; 2022
B Farhood (1797_CR141) 2019; 234
X Wang (1797_CR239) 2022; 145
Z Chen (1797_CR103) 2022; 13
C Kohnepoushi (1797_CR130) 2019; 48
EJ Wherry (1797_CR86) 2011; 12
J Chen (1797_CR207) 2022; 119
L Jia (1797_CR226) 2020; 10
H Sung (1797_CR2) 2021; 71
W Ma (1797_CR293) 2021; 6
JE Won (1797_CR190) 2021; 136
U Sahin (1797_CR271) 2018; 359
B Kupikowska-Stobba (1797_CR218) 2021; 9
1797_CR71
1797_CR72
1797_CR77
W Lin (1797_CR135) 2021; 16
R Zhu (1797_CR100) 2022; 12
P Badiee (1797_CR148) 2022; 622
JE Zuckerman (1797_CR312) 2014; 111
T Ishikawa (1797_CR313) 2021; 70
GK Alderton (1797_CR44) 2014; 14
MP Dias (1797_CR262) 2021; 18
1797_CR79
1797_CR206
Y Zhang (1797_CR51) 2020; 17
JBE Janssen (1797_CR47) 2022; 109
Y Liu (1797_CR7) 2016; 94
Z Chen (1797_CR131) 2020; 158
R Deng (1797_CR253) 2022; 13
C Sun (1797_CR34) 2018; 48
B Routy (1797_CR278) 2018; 359
D Ding (1797_CR110) 2018; 92
RZ Tang (1797_CR152) 2021; 9
E Samaridou (1797_CR200) 2020; 154–155
SY Kim (1797_CR223) 2019; 13
Y Zeng (1797_CR9) 2022; 12
C Ngambenjawong (1797_CR52) 2017; 114
1797_CR63
L Miao (1797_CR194) 2021; 20
DJ Irvine (1797_CR96) 2020; 20
T Fu (1797_CR38) 2021; 14
1797_CR67
HM Chen (1797_CR162) 2018; 128
OE Rahma (1797_CR27) 2019; 25
H Zhang (1797_CR28) 2017; 36
X Xiang (1797_CR46) 2022; 67
A Kheirolomoom (1797_CR209) 2022; 281
1797_CR68
References_xml – volume: 12
  start-page: 11740
  issue: 12
  year: 2018
  ident: 1797_CR53
  publication-title: ACS Nano
  doi: 10.1021/acsnano.8b05893
– volume: 9
  start-page: 1521
  issue: 6
  year: 2021
  ident: 1797_CR152
  publication-title: J Mater Chem B
  doi: 10.1039/D0TB02737E
– volume: 15
  start-page: 83
  issue: 1
  year: 2022
  ident: 1797_CR48
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-022-01305-4
– ident: 1797_CR284
  doi: 10.1016/j.it.2022.08.004
– volume: 345
  start-page: 306
  year: 2022
  ident: 1797_CR208
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2022.03.021
– volume: 266
  year: 2021
  ident: 1797_CR260
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2020.120469
– volume: 16
  start-page: 25
  issue: 1
  year: 2021
  ident: 1797_CR107
  publication-title: Nat Nanotechnol
  doi: 10.1038/s41565-020-00822-y
– volume: 18
  start-page: 773
  issue: 12
  year: 2021
  ident: 1797_CR262
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-021-00532-x
– volume: 21
  start-page: 8418
  issue: 19
  year: 2021
  ident: 1797_CR140
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.1c03004
– volume: 41
  start-page: 971
  issue: 7
  year: 2022
  ident: 1797_CR25
  publication-title: Oncogene
  doi: 10.1038/s41388-021-02132-6
– volume: 28
  start-page: 1342
  issue: 1
  year: 2021
  ident: 1797_CR113
  publication-title: Drug Deliv
  doi: 10.1080/10717544.2021.1943056
– ident: 1797_CR23
  doi: 10.3390/ijms22020843
– volume: 15
  start-page: 104
  issue: 1
  year: 2022
  ident: 1797_CR62
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-022-01322-3
– volume: 10
  start-page: 172
  year: 2019
  ident: 1797_CR248
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.00172
– volume: 27
  start-page: 1248
  issue: 1
  year: 2020
  ident: 1797_CR92
  publication-title: Drug Deliv
  doi: 10.1080/10717544.2020.1809559
– volume: 31
  start-page: 6867
  issue: 26
  year: 2010
  ident: 1797_CR203
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2010.05.027
– ident: 1797_CR101
  doi: 10.3390/nano12172948
– ident: 1797_CR91
  doi: 10.1039/d2tb00387b
– volume: 9
  start-page: 2076
  year: 2018
  ident: 1797_CR54
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.02076
– volume: 18
  start-page: 197
  issue: 3
  year: 2019
  ident: 1797_CR83
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-018-0007-y
– volume: 12
  start-page: 492
  issue: 6
  year: 2011
  ident: 1797_CR86
  publication-title: Nat Immunol
  doi: 10.1038/ni.2035
– volume: 6
  start-page: 4816
  issue: 9
  year: 2020
  ident: 1797_CR255
  publication-title: ACS Biomater Sci Eng
  doi: 10.1021/acsbiomaterials.0c00883
– volume: 23
  start-page: 373
  issue: 4
  year: 2022
  ident: 1797_CR124
  publication-title: Curr Drug Targets
  doi: 10.2174/1389450122666210906121803
– ident: 1797_CR122
  doi: 10.3390/nano12050836
– volume: 14
  start-page: 85
  issue: 1
  year: 2021
  ident: 1797_CR289
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01096-0
– volume: 15
  start-page: 2685
  year: 2020
  ident: 1797_CR234
  publication-title: Int J Nanomedicine
  doi: 10.2147/IJN.S242463
– volume: 18
  start-page: 181
  issue: 1
  year: 2019
  ident: 1797_CR24
  publication-title: Oncol Lett
– volume: 8
  start-page: 726
  issue: 9
  year: 2022
  ident: 1797_CR81
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2022.04.004
– volume: 343
  start-page: 379
  year: 2022
  ident: 1797_CR93
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2022.01.049
– volume: 359
  start-page: 1355
  issue: 6382
  year: 2018
  ident: 1797_CR271
  publication-title: Science
  doi: 10.1126/science.aar7112
– volume: 12
  start-page: 34658
  issue: 31
  year: 2020
  ident: 1797_CR235
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.0c09484
– volume: 348
  start-page: 1066
  year: 2022
  ident: 1797_CR182
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2022.06.012
– volume: 216
  issue: 6
  year: 2020
  ident: 1797_CR224
  publication-title: Pathol Res Pract
  doi: 10.1016/j.prp.2020.152954
– volume: 60
  start-page: 1638
  issue: 15
  year: 2008
  ident: 1797_CR119
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2008.08.002
– volume: 187
  year: 2022
  ident: 1797_CR183
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2022.114395
– ident: 1797_CR13
  doi: 10.1016/j.semcancer.2022.08.004
– volume: 73
  start-page: 38
  year: 2018
  ident: 1797_CR127
  publication-title: Acta Biomater
  doi: 10.1016/j.actbio.2018.04.006
– volume: 40
  start-page: 586
  issue: 6
  year: 2022
  ident: 1797_CR281
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.21.01497
– volume: 97
  year: 2021
  ident: 1797_CR30
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2021.107683
– volume: 34
  start-page: 82
  issue: 1
  year: 2015
  ident: 1797_CR158
  publication-title: Int Rev Immunol
  doi: 10.3109/08830185.2014.969421
– volume: 12
  start-page: 3295
  issue: 4
  year: 2018
  ident: 1797_CR164
  publication-title: ACS Nano
  doi: 10.1021/acsnano.7b08148
– volume: 12
  year: 2022
  ident: 1797_CR254
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.931995
– volume: 48
  start-page: 3771
  issue: 14
  year: 2019
  ident: 1797_CR102
  publication-title: Chem Soc Rev
  doi: 10.1039/C8CS00896E
– ident: 1797_CR232
  doi: 10.3390/nano12142337
– volume: 245
  year: 2020
  ident: 1797_CR216
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2020.117394
– ident: 1797_CR285
  doi: 10.1007/s00262-022-03260-y
– ident: 1797_CR297
  doi: 10.3390/cancers12010213
– volume: 33
  issue: 49
  year: 2021
  ident: 1797_CR241
  publication-title: Adv Mater
  doi: 10.1002/adma.202103936
– volume: 20
  start-page: 97
  issue: 1
  year: 2022
  ident: 1797_CR58
  publication-title: Cell Commun Signal
  doi: 10.1186/s12964-022-00904-5
– volume: 25
  start-page: 347
  issue: 5
  year: 2021
  ident: 1797_CR80
  publication-title: Expert Opin Ther Targets
  doi: 10.1080/14728222.2021.1937123
– volume: 9
  start-page: 5221
  issue: 26
  year: 2021
  ident: 1797_CR218
  publication-title: J Mater Chem B
  doi: 10.1039/D1TB00559F
– volume: 115
  start-page: 243
  year: 2017
  ident: 1797_CR104
  publication-title: Eur J Pharm Biopharm
  doi: 10.1016/j.ejpb.2017.03.013
– volume: 145
  start-page: 235
  year: 2022
  ident: 1797_CR239
  publication-title: Acta Biomater
  doi: 10.1016/j.actbio.2022.04.001
– volume: 29
  start-page: 56
  issue: 1
  year: 2022
  ident: 1797_CR45
  publication-title: J Biomed Sci
  doi: 10.1186/s12929-022-00837-8
– volume: 9
  start-page: 8073
  issue: 26
  year: 2019
  ident: 1797_CR303
  publication-title: Theranostics
  doi: 10.7150/thno.37198
– volume: 21
  start-page: 64
  issue: 4
  year: 2019
  ident: 1797_CR105
  publication-title: AAPS J
  doi: 10.1208/s12248-019-0333-y
– volume: 17
  start-page: 1326
  issue: 3
  year: 2017
  ident: 1797_CR205
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.6b03329
– volume: 12
  start-page: 56741
  issue: 51
  year: 2020
  ident: 1797_CR236
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.0c16728
– volume: 36
  start-page: 2095
  issue: 15
  year: 2017
  ident: 1797_CR28
  publication-title: Oncogene
  doi: 10.1038/onc.2016.367
– volume: 95
  year: 2021
  ident: 1797_CR132
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2021.107532
– volume: 17
  start-page: 807
  issue: 8
  year: 2020
  ident: 1797_CR51
  publication-title: Cell Mol Immunol
  doi: 10.1038/s41423-020-0488-6
– volume: 189
  year: 2022
  ident: 1797_CR176
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2022.114503
– volume: 7
  start-page: 319
  issue: 5
  year: 2016
  ident: 1797_CR195
  publication-title: Ther Deliv
  doi: 10.4155/tde-2016-0006
– volume: 281
  year: 2022
  ident: 1797_CR209
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2021.121339
– volume: 32
  issue: 47
  year: 2020
  ident: 1797_CR242
  publication-title: Adv Mater
  doi: 10.1002/adma.202002085
– ident: 1797_CR265
  doi: 10.1186/s13054-017-1678-1
– volume: 154–155
  start-page: 37
  year: 2020
  ident: 1797_CR200
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2020.06.002
– ident: 1797_CR233
  doi: 10.3390/pharmaceutics14061127
– volume: 377
  start-page: 1836
  issue: 19
  year: 2017
  ident: 1797_CR4
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1701830
– volume: 9
  start-page: 3892
  issue: 18
  year: 2021
  ident: 1797_CR187
  publication-title: J Mater Chem B
  doi: 10.1039/D1TB00256B
– volume: 22
  start-page: 8801
  issue: 22
  year: 2022
  ident: 1797_CR193
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.2c01994
– volume: 17
  start-page: 147
  year: 2022
  ident: 1797_CR191
  publication-title: Bioact Mater
  doi: 10.1016/j.bioactmat.2022.01.003
– volume: 128
  start-page: 1971
  issue: 5
  year: 2018
  ident: 1797_CR222
  publication-title: J Clin Invest
  doi: 10.1172/JCI96791
– ident: 1797_CR246
  doi: 10.1016/j.vaccine.2022.06.043
– volume: 48
  start-page: 2053
  issue: 7
  year: 2019
  ident: 1797_CR292
  publication-title: Chem Soc Rev
  doi: 10.1039/C8CS00618K
– volume: 9
  year: 2022
  ident: 1797_CR89
  publication-title: Front Mol Biosci
  doi: 10.3389/fmolb.2022.900344
– volume: 22
  start-page: 6606
  issue: 16
  year: 2022
  ident: 1797_CR143
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.2c01863
– volume: 143
  start-page: 3050
  issue: 12
  year: 2018
  ident: 1797_CR94
  publication-title: Int J Cancer
  doi: 10.1002/ijc.31717
– volume: 17
  issue: 52
  year: 2021
  ident: 1797_CR168
  publication-title: Small
  doi: 10.1002/smll.202104773
– volume: 54
  start-page: 162
  issue: 2
  year: 2001
  ident: 1797_CR118
  publication-title: J Biomed Mater Res
  doi: 10.1002/1097-4636(200102)54:2<162::AID-JBM2>3.0.CO;2-3
– volume: 23
  start-page: 92
  issue: 4
  year: 2021
  ident: 1797_CR114
  publication-title: AAPS J
  doi: 10.1208/s12248-021-00611-y
– volume: 19
  start-page: 2677
  issue: 5
  year: 2020
  ident: 1797_CR220
  publication-title: Compr Rev Food Sci Food Saf
  doi: 10.1111/1541-4337.12604
– ident: 1797_CR286
  doi: 10.3390/cancers14163908
– volume: 244
  start-page: 108
  issue: Pt A
  year: 2016
  ident: 1797_CR302
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2016.11.015
– volume: 22
  start-page: 5183
  issue: 21
  year: 2016
  ident: 1797_CR73
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-16-0933
– volume: 52
  start-page: 728
  issue: 2
  year: 2023
  ident: 1797_CR123
  publication-title: Chem Soc Rev
  doi: 10.1039/D2CS00106C
– volume: 7
  start-page: 28
  issue: 3
  year: 2018
  ident: 1797_CR269
  publication-title: Chin Clin Oncol
  doi: 10.21037/cco.2018.05.05
– volume: 6
  start-page: 243
  issue: 3
  year: 2022
  ident: 1797_CR146
  publication-title: Nanotheranostics
  doi: 10.7150/ntno.65544
– ident: 1797_CR49
  doi: 10.3390/ijms22115801
– volume: 93
  start-page: 52
  year: 2015
  ident: 1797_CR264
  publication-title: Eur J Pharm Biopharm
  doi: 10.1016/j.ejpb.2015.03.018
– ident: 1797_CR35
  doi: 10.1016/j.ccell.2020.09.001
– volume: 13
  year: 2022
  ident: 1797_CR253
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.923477
– ident: 1797_CR175
  doi: 10.3390/biom11121850
– volume: 359
  start-page: 91
  issue: 6371
  year: 2018
  ident: 1797_CR278
  publication-title: Science
  doi: 10.1126/science.aan3706
– volume: 575
  start-page: 299
  issue: 7782
  year: 2019
  ident: 1797_CR10
  publication-title: Nature
  doi: 10.1038/s41586-019-1730-1
– volume: 337
  start-page: 329
  year: 2021
  ident: 1797_CR144
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2021.07.035
– ident: 1797_CR40
  doi: 10.1007/s00262-022-03343-w
– volume: 154–155
  start-page: 102
  year: 2020
  ident: 1797_CR179
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2020.07.002
– volume: 44
  start-page: 51
  year: 2016
  ident: 1797_CR283
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2016.02.001
– volume: 15
  start-page: 3123
  issue: 2
  year: 2021
  ident: 1797_CR186
  publication-title: ACS Nano
  doi: 10.1021/acsnano.0c09681
– volume: 111
  start-page: 11449
  issue: 31
  year: 2014
  ident: 1797_CR312
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1411393111
– volume: 14
  start-page: 217
  issue: 1
  year: 2019
  ident: 1797_CR156
  publication-title: Nanoscale Res Lett
  doi: 10.1186/s11671-019-3032-9
– volume: 1865
  issue: 12
  year: 2019
  ident: 1797_CR41
  publication-title: Biochim Biophys Acta Mol Basis Dis
  doi: 10.1016/j.bbadis.2019.165540
– ident: 1797_CR147
  doi: 10.1007/s00262-022-03209-1
– ident: 1797_CR68
  doi: 10.1126/scitranslmed.3003689
– volume: 16
  start-page: 2775
  year: 2021
  ident: 1797_CR135
  publication-title: Int J Nanomedicine
  doi: 10.2147/IJN.S301552
– volume: 62
  start-page: 4908
  issue: 18
  year: 2022
  ident: 1797_CR219
  publication-title: Crit Rev Food Sci Nutr
  doi: 10.1080/10408398.2021.1879727
– volume: 382
  start-page: 1894
  issue: 20
  year: 2020
  ident: 1797_CR273
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1915745
– ident: 1797_CR63
  doi: 10.3390/cells11121974
– volume: 354
  start-page: 1160
  issue: 6316
  year: 2016
  ident: 1797_CR69
  publication-title: Science
  doi: 10.1126/science.aaf2807
– volume: 128
  start-page: 5647
  issue: 12
  year: 2018
  ident: 1797_CR162
  publication-title: J Clin Invest
  doi: 10.1172/JCI97570
– ident: 1797_CR198
  doi: 10.3390/molecules27175607
– ident: 1797_CR199
  doi: 10.3389/fmolb.2020.587997
– volume: 22
  start-page: 2826
  issue: 7
  year: 2022
  ident: 1797_CR252
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.1c04888
– volume: 9
  start-page: 96
  issue: 1
  year: 2019
  ident: 1797_CR174
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-18-0065
– volume: 268
  year: 2021
  ident: 1797_CR256
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2020.120560
– ident: 1797_CR250
  doi: 10.1101/cshperspect.a030338
– volume: 12
  start-page: 3233
  issue: 8
  year: 2022
  ident: 1797_CR9
  publication-title: Acta Pharm Sin B
  doi: 10.1016/j.apsb.2022.02.023
– ident: 1797_CR18
  doi: 10.7554/eLife.79895
– volume: 11
  start-page: 5417
  issue: 6
  year: 2017
  ident: 1797_CR308
  publication-title: ACS Nano
  doi: 10.1021/acsnano.6b08152
– volume: 370
  start-page: 1
  year: 2022
  ident: 1797_CR20
  publication-title: Int Rev Cell Mol Biol
  doi: 10.1016/bs.ircmb.2022.03.002
– ident: 1797_CR67
  doi: 10.1016/j.trecan.2022.05.005
– volume: 9
  start-page: 805
  issue: 7
  year: 2012
  ident: 1797_CR125
  publication-title: Expert Opin Drug Deliv
  doi: 10.1517/17425247.2012.689284
– volume: 52
  start-page: 481
  issue: 3
  year: 2022
  ident: 1797_CR257
  publication-title: Crit Rev Anal Chem
  doi: 10.1080/10408347.2020.1808442
– volume: 25
  start-page: 313
  issue: 5
  year: 2021
  ident: 1797_CR172
  publication-title: OMICS
  doi: 10.1089/omi.2021.0025
– volume: 2022
  start-page: 3119375
  year: 2022
  ident: 1797_CR22
  publication-title: J Immunol Res
  doi: 10.1155/2022/3119375
– ident: 1797_CR154
  doi: 10.1002/mabi.201700092
– volume: 14
  start-page: 3927
  issue: 4
  year: 2020
  ident: 1797_CR240
  publication-title: ACS Nano
  doi: 10.1021/acsnano.9b06111
– volume: 54
  start-page: 720
  issue: 6
  year: 2022
  ident: 1797_CR16
  publication-title: Exp Mol Med
  doi: 10.1038/s12276-022-00784-2
– ident: 1797_CR82
  doi: 10.1126/scitranslmed.abo3605
– volume: 6
  start-page: 1078
  issue: 12
  year: 2021
  ident: 1797_CR196
  publication-title: Nat Rev Mater
  doi: 10.1038/s41578-021-00358-0
– volume: 39
  start-page: 583
  year: 2021
  ident: 1797_CR268
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev-immunol-110519-071134
– volume: 21
  start-page: 28
  issue: 1
  year: 2022
  ident: 1797_CR277
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01489-2
– ident: 1797_CR1
  doi: 10.1146/annurev-cellbio-120420-125117
– volume: 18
  issue: 42
  year: 2022
  ident: 1797_CR171
  publication-title: Small
  doi: 10.1002/smll.202203466
– volume: 119
  issue: 34
  year: 2022
  ident: 1797_CR207
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.2207841119
– volume: 10
  start-page: 7921
  issue: 17
  year: 2020
  ident: 1797_CR301
  publication-title: Theranostics
  doi: 10.7150/thno.49577
– ident: 1797_CR221
  doi: 10.3390/nano10081608
– volume: 67
  start-page: 35
  year: 2022
  ident: 1797_CR46
  publication-title: Cytokine Growth Factor Rev
  doi: 10.1016/j.cytogfr.2022.07.006
– volume: 19
  start-page: 3381
  issue: 4
  year: 2021
  ident: 1797_CR215
  publication-title: Environ Chem Lett
  doi: 10.1007/s10311-021-01216-9
– volume: 188
  year: 2022
  ident: 1797_CR65
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2022.114415
– volume: 38
  start-page: 3484
  issue: 12
  year: 2009
  ident: 1797_CR117
  publication-title: Chem Soc Rev
  doi: 10.1039/b820162p
– volume: 22
  start-page: 729
  issue: 5
  year: 2019
  ident: 1797_CR33
  publication-title: Nat Neurosci
  doi: 10.1038/s41593-019-0370-y
– ident: 1797_CR6
  doi: 10.1016/j.canlet.2022.215823
– volume: 275
  year: 2021
  ident: 1797_CR189
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2021.120964
– ident: 1797_CR71
  doi: 10.1016/j.ccell.2021.07.007
– volume: 234
  start-page: 8509
  issue: 6
  year: 2019
  ident: 1797_CR141
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.27782
– volume: 8
  start-page: e2100712
  issue: 14
  year: 2021
  ident: 1797_CR299
  publication-title: Adv Sci (Weinh).
  doi: 10.1002/advs.202100712
– volume: 12
  start-page: 7397
  issue: 24
  year: 2006
  ident: 1797_CR316
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-1546
– volume: 14
  start-page: 45
  issue: 1
  year: 2021
  ident: 1797_CR84
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01056-8
– volume: 110
  year: 2020
  ident: 1797_CR112
  publication-title: Mater Sci Eng C Mater Biol Appl
  doi: 10.1016/j.msec.2020.110698
– volume: 170
  start-page: 424
  year: 2021
  ident: 1797_CR170
  publication-title: Int J Biol Macromol
  doi: 10.1016/j.ijbiomac.2020.12.161
– volume: 19
  start-page: 775
  issue: 12
  year: 2022
  ident: 1797_CR78
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-022-00689-z
– volume: 11
  start-page: 4835
  issue: 1
  year: 2020
  ident: 1797_CR142
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-18570-x
– volume: 10
  start-page: 633
  issue: 3
  year: 2022
  ident: 1797_CR217
  publication-title: Biomater Sci
  doi: 10.1039/D1BM01537K
– volume: 354
  start-page: 1165
  issue: 6316
  year: 2016
  ident: 1797_CR70
  publication-title: Science
  doi: 10.1126/science.aae0491
– volume: 41
  start-page: 4
  issue: 1
  year: 2020
  ident: 1797_CR64
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2019.11.003
– ident: 1797_CR317
  doi: 10.1056/NEJMoa1809615
– ident: 1797_CR181
  doi: 10.1016/j.lfs.2022.120734
– volume: 12
  start-page: 5121
  issue: 6
  year: 2018
  ident: 1797_CR138
  publication-title: ACS Nano
  doi: 10.1021/acsnano.7b09041
– volume: 60
  start-page: 10647
  issue: 19
  year: 2021
  ident: 1797_CR227
  publication-title: Angew Chem Int Ed Engl
  doi: 10.1002/anie.202015590
– ident: 1797_CR97
  doi: 10.1021/acsami.2c08619
– volume: 18
  start-page: 985
  issue: 9
  year: 2017
  ident: 1797_CR157
  publication-title: Nat Immunol
  doi: 10.1038/ni.3796
– volume: 59
  start-page: 1677
  issue: 5
  year: 2022
  ident: 1797_CR213
  publication-title: J Food Sci Technol
  doi: 10.1007/s13197-021-05128-y
– volume: 344
  start-page: 289
  year: 2022
  ident: 1797_CR295
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2022.01.034
– ident: 1797_CR206
  doi: 10.3390/life11040269
– volume: 10
  start-page: 9956
  issue: 22
  year: 2020
  ident: 1797_CR226
  publication-title: Theranostics
  doi: 10.7150/thno.46089
– volume: 136
  start-page: 508
  year: 2021
  ident: 1797_CR190
  publication-title: Acta Biomater
  doi: 10.1016/j.actbio.2021.09.062
– volume: 288
  year: 2022
  ident: 1797_CR150
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2022.121677
– ident: 1797_CR72
  doi: 10.1136/jitc-2020-000957
– volume: 28
  start-page: 1397
  issue: 1
  year: 2021
  ident: 1797_CR109
  publication-title: Drug Deliv
  doi: 10.1080/10717544.2021.1938756
– volume: 158
  year: 2020
  ident: 1797_CR131
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2020.104902
– volume: 8
  start-page: 70
  issue: 1
  year: 2020
  ident: 1797_CR314
  publication-title: Immunol Res
– volume: 37
  start-page: 457
  year: 2019
  ident: 1797_CR85
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev-immunol-041015-055318
– ident: 1797_CR287
  doi: 10.1002/wnan.1842
– volume: 41
  start-page: 1622
  issue: 3
  year: 2021
  ident: 1797_CR161
  publication-title: Med Res Rev
  doi: 10.1002/med.21771
– volume: 335
  start-page: 306
  year: 2021
  ident: 1797_CR188
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2021.05.040
– ident: 1797_CR212
  doi: 10.3390/nano10020364
– volume: 23
  start-page: 1309
  issue: 9
  year: 2022
  ident: 1797_CR59
  publication-title: Nat Immunol
  doi: 10.1038/s41590-022-01291-2
– volume: 20
  start-page: 484
  issue: 1
  year: 2022
  ident: 1797_CR245
  publication-title: J Nanobiotechnology
  doi: 10.1186/s12951-022-01692-3
– volume: 20
  start-page: 62
  issue: 1
  year: 2022
  ident: 1797_CR163
  publication-title: J Nanobiotechnology
  doi: 10.1186/s12951-022-01270-7
– volume: 9
  start-page: 32
  issue: 1
  year: 2022
  ident: 1797_CR98
  publication-title: Nano convergence
  doi: 10.1186/s40580-022-00322-w
– ident: 1797_CR274
  doi: 10.1056/NEJMoa1503093
– volume: 110
  year: 2022
  ident: 1797_CR56
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2022.102461
– volume: 135
  year: 2022
  ident: 1797_CR99
  publication-title: Biomater Adv
  doi: 10.1016/j.bioadv.2022.212725
– volume: 12
  year: 2022
  ident: 1797_CR100
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.930125
– ident: 1797_CR17
  doi: 10.1136/jitc-2022-004863
– volume: 109
  year: 2022
  ident: 1797_CR47
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2022.102433
– volume: 15
  start-page: 486
  issue: 8
  year: 2015
  ident: 1797_CR50
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3862
– ident: 1797_CR21
  doi: 10.3390/cancers14123021
– volume: 11
  start-page: 9937
  issue: 20
  year: 2021
  ident: 1797_CR291
  publication-title: Theranostics
  doi: 10.7150/thno.65480
– volume: 367
  start-page: 446
  issue: 6476
  year: 2020
  ident: 1797_CR311
  publication-title: Science
  doi: 10.1126/science.aay5967
– volume: 20
  start-page: 286
  issue: 6
  year: 2020
  ident: 1797_CR173
  publication-title: Exp Ther Med
  doi: 10.3892/etm.2020.9416
– volume: 16
  start-page: 151
  issue: 3
  year: 2019
  ident: 1797_CR74
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-018-0142-8
– volume: 345
  start-page: 512
  year: 2022
  ident: 1797_CR304
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2022.03.043
– volume: 48
  start-page: 794
  issue: 8
  year: 2019
  ident: 1797_CR130
  publication-title: Immunol Invest
  doi: 10.1080/08820139.2019.1610889
– volume: 35
  start-page: 168
  issue: 1
  year: 2016
  ident: 1797_CR129
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-016-0444-6
– ident: 1797_CR282
  doi: 10.3390/cancers12061475
– volume: 34
  issue: 16
  year: 2022
  ident: 1797_CR155
  publication-title: Adv Mater
  doi: 10.1002/adma.202109178
– volume: 14
  start-page: 136
  issue: 3
  year: 2014
  ident: 1797_CR44
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3634
– volume: 16
  start-page: 1260
  issue: 11
  year: 2021
  ident: 1797_CR243
  publication-title: Nat Nanotechnol
  doi: 10.1038/s41565-021-00962-9
– volume: 55
  start-page: 2
  issue: 1
  year: 2022
  ident: 1797_CR201
  publication-title: Acc Chem Res
  doi: 10.1021/acs.accounts.1c00544
– ident: 1797_CR87
  doi: 10.1016/j.jconrel.2022.09.012
– volume: 10
  year: 2022
  ident: 1797_CR108
  publication-title: Front Chem
  doi: 10.3389/fchem.2022.973666
– ident: 1797_CR77
  doi: 10.1126/scitranslmed.aan3311
– volume: 6
  start-page: 346
  issue: 2
  year: 2021
  ident: 1797_CR126
  publication-title: Bioact Mater
  doi: 10.1016/j.bioactmat.2020.08.016
– volume: 20
  start-page: 1388
  issue: 8
  year: 2021
  ident: 1797_CR32
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-20-0591
– ident: 1797_CR294
  doi: 10.3390/pharmaceutics14081630
– volume: 36
  start-page: 707
  issue: 8
  year: 2018
  ident: 1797_CR319
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.4181
– volume: 601
  year: 2021
  ident: 1797_CR180
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2021.120571
– volume: 5
  start-page: 38
  issue: 1
  year: 2020
  ident: 1797_CR29
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-020-0144-8
– volume: 13
  start-page: 12671
  issue: 11
  year: 2019
  ident: 1797_CR223
  publication-title: ACS Nano
  doi: 10.1021/acsnano.9b04207
– ident: 1797_CR153
  doi: 10.4274/tjps.galenos.2019.48751
– volume: 172
  start-page: 426
  issue: 2
  year: 2013
  ident: 1797_CR305
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2013.05.037
– volume: 70
  start-page: 3081
  issue: 11
  year: 2021
  ident: 1797_CR313
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-021-02892-w
– volume: 78
  start-page: 90
  year: 2022
  ident: 1797_CR267
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2021.04.021
– volume: 18
  start-page: 4015
  issue: 11
  year: 2021
  ident: 1797_CR300
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.1c00448
– volume: 189
  year: 2022
  ident: 1797_CR231
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2022.114524
– volume: 131
  start-page: 58
  issue: 1
  year: 2018
  ident: 1797_CR279
  publication-title: Blood
  doi: 10.1182/blood-2017-06-741033
– volume: 15
  start-page: 118
  issue: 1
  year: 2022
  ident: 1797_CR57
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-022-01335-y
– volume: 14
  start-page: 89
  issue: 1
  year: 2019
  ident: 1797_CR160
  publication-title: Nat Nanotechnol
  doi: 10.1038/s41565-018-0319-4
– volume: 15
  start-page: 120
  issue: 1
  year: 2022
  ident: 1797_CR19
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-022-01340-1
– volume: 14
  start-page: 11067
  issue: 9
  year: 2020
  ident: 1797_CR225
  publication-title: ACS Nano
  doi: 10.1021/acsnano.9b10103
– volume: 326
  start-page: 297
  year: 2020
  ident: 1797_CR244
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2020.07.008
– volume: 10
  start-page: 4944
  issue: 11
  year: 2020
  ident: 1797_CR259
  publication-title: Theranostics
  doi: 10.7150/thno.42471
– volume: 622
  year: 2022
  ident: 1797_CR148
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2022.121845
– volume: 12
  year: 2021
  ident: 1797_CR134
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.641703
– volume: 200
  start-page: 408
  issue: 7
  year: 2014
  ident: 1797_CR3
  publication-title: Med J Aust
  doi: 10.5694/mja13.11182
– volume: 39
  start-page: 1181
  issue: 9
  year: 2016
  ident: 1797_CR121
  publication-title: Arch Pharm Res
  doi: 10.1007/s12272-016-0782-0
– volume: 12
  start-page: 4779
  issue: 10
  year: 2022
  ident: 1797_CR178
  publication-title: Theranostics
  doi: 10.7150/thno.72339
– volume: 12
  start-page: 935
  year: 2017
  ident: 1797_CR167
  publication-title: Int J Nanomedicine
  doi: 10.2147/IJN.S121881
– volume: 15
  start-page: 111
  issue: 1
  year: 2022
  ident: 1797_CR61
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-022-01325-0
– volume: 348
  start-page: 250
  year: 2022
  ident: 1797_CR149
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2022.05.057
– ident: 1797_CR106
  doi: 10.1038/s41417-021-00299-4
– ident: 1797_CR79
  doi: 10.1038/s41467-020-18298-8
– volume: 24
  start-page: 511
  issue: 3
  year: 2018
  ident: 1797_CR272
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-16-3001
– volume: 6
  start-page: 446
  issue: 4
  year: 2016
  ident: 1797_CR75
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-15-0944
– ident: 1797_CR258
  doi: 10.3390/ijms19113564
– volume: 14
  start-page: 1012841
  year: 2023
  ident: 1797_CR276
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2023.1012841
– volume: 20
  start-page: 321
  issue: 5
  year: 2020
  ident: 1797_CR96
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-019-0269-6
– volume: 12
  start-page: 809
  issue: 7
  year: 2013
  ident: 1797_CR139
  publication-title: Expert Rev Vaccines
  doi: 10.1586/14760584.2013.811208
– volume: 255
  year: 2020
  ident: 1797_CR184
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2020.120190
– volume: 10
  start-page: 707
  year: 2019
  ident: 1797_CR137
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.00707
– volume: 15
  start-page: 246
  issue: 1
  year: 2021
  ident: 1797_CR42
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12834
– ident: 1797_CR90
  doi: 10.1002/adma.202203890
– volume: 6
  start-page: 1075
  issue: 12
  year: 2021
  ident: 1797_CR197
  publication-title: Nat Rev Mater
  doi: 10.1038/s41578-021-00379-9
– volume: 8
  start-page: 915
  issue: 11
  year: 2022
  ident: 1797_CR261
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2022.06.009
– volume: 6
  start-page: 351
  issue: 1
  year: 2021
  ident: 1797_CR293
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-021-00727-9
– volume: 14
  start-page: 98
  issue: 1
  year: 2021
  ident: 1797_CR38
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01103-4
– volume: 19
  start-page: 328
  issue: 1
  year: 2021
  ident: 1797_CR238
  publication-title: J Nanobiotechnol
  doi: 10.1186/s12951-021-01073-2
– volume: 59
  start-page: 478
  issue: 6
  year: 2007
  ident: 1797_CR202
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2007.04.007
– volume: 37
  year: 2021
  ident: 1797_CR228
  publication-title: Nanomedicine
  doi: 10.1016/j.nano.2021.102415
– ident: 1797_CR229
  doi: 10.3390/pharmaceutics14010196
– volume: 12
  year: 2021
  ident: 1797_CR36
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.715234
– ident: 1797_CR192
  doi: 10.1126/sciadv.abc9450
– volume: 450
  start-page: 145
  issue: 1–2
  year: 2013
  ident: 1797_CR116
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2013.04.063
– ident: 1797_CR115
  doi: 10.1080/17425247.2016.1182485
– ident: 1797_CR270
  doi: 10.3390/cancers14163972
– volume: 22
  start-page: 1403
  issue: 11
  year: 2021
  ident: 1797_CR159
  publication-title: Nat Immunol
  doi: 10.1038/s41590-021-01047-4
– volume: 11
  start-page: 3089
  issue: 3
  year: 2017
  ident: 1797_CR306
  publication-title: ACS Nano
  doi: 10.1021/acsnano.7b00078
– volume: 6
  start-page: 31
  issue: 1
  year: 2022
  ident: 1797_CR66
  publication-title: NPJ Prec Oncol
  doi: 10.1038/s41698-022-00272-w
– volume: 39
  start-page: 186
  issue: 2
  year: 2021
  ident: 1797_CR251
  publication-title: Nat Biotechnol
  doi: 10.1038/s41587-020-0651-8
– volume: 71
  start-page: 209
  issue: 3
  year: 2021
  ident: 1797_CR2
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21660
– ident: 1797_CR11
  doi: 10.1016/j.bbcan.2022.188797
– ident: 1797_CR39
  doi: 10.3390/ijms222413310
– ident: 1797_CR128
  doi: 10.3390/ijms22168884
– volume: 8
  start-page: 1747
  issue: 1
  year: 2017
  ident: 1797_CR307
  publication-title: Nat Commun
  doi: 10.1038/s41467-017-01830-8
– volume: 59
  year: 2021
  ident: 1797_CR8
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2021.100796
– volume: 21
  start-page: 313
  issue: 5
  year: 2021
  ident: 1797_CR263
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-021-00340-6
– volume: 20
  start-page: 41
  issue: 1
  year: 2021
  ident: 1797_CR194
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01335-5
– volume: 163
  start-page: 891
  issue: 4
  year: 2022
  ident: 1797_CR26
  publication-title: Gastroenterology.
  doi: 10.1053/j.gastro.2022.06.024
– volume: 57
  start-page: 321
  year: 2015
  ident: 1797_CR151
  publication-title: Mater Sci Eng C Mater Biol Appl
  doi: 10.1016/j.msec.2015.08.006
– volume: 110
  start-page: 553
  issue: 2
  year: 2007
  ident: 1797_CR37
  publication-title: Blood
  doi: 10.1182/blood-2006-11-059246
– ident: 1797_CR12
  doi: 10.1016/j.phrs.2022.106425
– volume: 25
  start-page: 5449
  issue: 18
  year: 2019
  ident: 1797_CR27
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-1543
– volume: 114
  start-page: 206
  year: 2017
  ident: 1797_CR52
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2017.04.010
– volume: 223
  year: 2019
  ident: 1797_CR111
  publication-title: Carbohydr Polym
  doi: 10.1016/j.carbpol.2019.115128
– volume: 78
  start-page: 3718
  issue: 13
  year: 2018
  ident: 1797_CR309
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-18-0306
– volume: 50
  start-page: 778
  issue: 4
  year: 2019
  ident: 1797_CR210
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.03.012
– volume: 204
  year: 2020
  ident: 1797_CR230
  publication-title: J Photochem Photobiol B
  doi: 10.1016/j.jphotobiol.2020.111808
– volume: 12
  start-page: 2935
  issue: 1
  year: 2021
  ident: 1797_CR136
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-23244-3
– volume: 188
  year: 2022
  ident: 1797_CR15
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2022.114444
– volume: 39
  start-page: 6
  issue: 1
  year: 2019
  ident: 1797_CR211
  publication-title: J Interferon Cytokine Res
  doi: 10.1089/jir.2018.0019
– ident: 1797_CR266
  doi: 10.1016/S1470-2045(16)30035-3
– volume: 33
  issue: 48
  year: 2021
  ident: 1797_CR169
  publication-title: Adv Mater
  doi: 10.1002/adma.202105667
– volume: 2019
  start-page: 3046379
  year: 2019
  ident: 1797_CR288
  publication-title: J Immunol Res
  doi: 10.1155/2019/3046379
– volume: 18
  start-page: 168
  issue: 3
  year: 2018
  ident: 1797_CR204
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri.2017.131
– volume: 18
  issue: 6
  year: 2022
  ident: 1797_CR290
  publication-title: Small
  doi: 10.1002/smll.202103868
– volume: 33
  start-page: 97
  issue: 1
  year: 2015
  ident: 1797_CR310
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3104
– volume: 44
  start-page: 2049
  issue: 6
  year: 2016
  ident: 1797_CR120
  publication-title: Ann Biomed Eng
  doi: 10.1007/s10439-016-1583-9
– volume: 92
  start-page: 1041
  year: 2018
  ident: 1797_CR110
  publication-title: Mater Sci Eng C Mater Biol Appl
  doi: 10.1016/j.msec.2017.12.036
– volume: 76
  start-page: 5241
  issue: 18
  year: 2016
  ident: 1797_CR43
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-15-3164
– volume: 10
  start-page: 1908
  issue: 12
  year: 2022
  ident: 1797_CR296
  publication-title: J Mater Chem B
  doi: 10.1039/D1TB02470A
– volume: 58
  start-page: 8754
  issue: 63
  year: 2022
  ident: 1797_CR14
  publication-title: Chem Commun (Camb)
  doi: 10.1039/D2CC02759C
– volume: 13
  start-page: 473
  issue: 8
  year: 2016
  ident: 1797_CR280
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2016.58
– ident: 1797_CR133
  doi: 10.3390/pharmaceutics12121165
– volume: 9
  start-page: 2165
  issue: 1
  year: 2018
  ident: 1797_CR165
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-04607-9
– volume: 108
  start-page: e111
  issue: 3
  year: 2021
  ident: 1797_CR5
  publication-title: Br J Surg
  doi: 10.1093/bjs/znaa123
– volume: 10
  start-page: 1042
  issue: 9
  year: 2022
  ident: 1797_CR60
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-22-0266
– volume: 34
  start-page: 1104
  issue: 10
  year: 2016
  ident: 1797_CR275
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.59.1586
– volume: 109
  start-page: 24
  year: 2016
  ident: 1797_CR145
  publication-title: Eur J Pharm Biopharm
  doi: 10.1016/j.ejpb.2016.08.012
– volume: 15
  start-page: 1437
  year: 2020
  ident: 1797_CR298
  publication-title: Int J Nanomedicine
  doi: 10.2147/IJN.S236927
– volume: 48
  start-page: 434
  issue: 3
  year: 2018
  ident: 1797_CR34
  publication-title: Immunity
  doi: 10.1016/j.immuni.2018.03.014
– volume: 12
  start-page: 813
  issue: 8
  year: 2017
  ident: 1797_CR318
  publication-title: Nat Nanotechnol
  doi: 10.1038/nnano.2017.57
– volume: 16
  start-page: 2107
  year: 2021
  ident: 1797_CR237
  publication-title: Int J Nanomedicine
  doi: 10.2147/IJN.S295565
– volume: 54
  start-page: 875
  issue: 5
  year: 2021
  ident: 1797_CR249
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.04.004
– volume: 11
  start-page: 246
  year: 2013
  ident: 1797_CR315
  publication-title: J Transl Med
  doi: 10.1186/1479-5876-11-246
– ident: 1797_CR55
  doi: 10.1093/annonc/mdx444
– volume: 13
  year: 2022
  ident: 1797_CR103
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.979469
– volume: 7
  issue: 7
  year: 2018
  ident: 1797_CR76
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1445949
– volume: 13
  start-page: 900
  issue: 10
  year: 2012
  ident: 1797_CR166
  publication-title: EMBO Rep
  doi: 10.1038/embor.2012.127
– volume: 218
  year: 2022
  ident: 1797_CR177
  publication-title: B, Biointerfaces
  doi: 10.1016/j.colsurfb.2022.112737
– volume: 19
  start-page: 303
  issue: 3
  year: 2022
  ident: 1797_CR214
  publication-title: Expert Opin Drug Deliv
  doi: 10.1080/17425247.2022.2045944
– volume: 94
  start-page: 509
  issue: 5
  year: 2016
  ident: 1797_CR7
  publication-title: J Mol Med (Berl)
  doi: 10.1007/s00109-015-1376-x
– ident: 1797_CR185
  doi: 10.1016/j.lfs.2020.118605
– volume: 13
  start-page: 47407
  issue: 40
  year: 2021
  ident: 1797_CR247
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.1c16154
– volume: 15
  start-page: 9159
  year: 2020
  ident: 1797_CR95
  publication-title: Int J Nanomedicine
  doi: 10.2147/IJN.S249252
– ident: 1797_CR88
  doi: 10.3390/pharmaceutics14081620
– volume: 2022
  start-page: 9910049
  year: 2022
  ident: 1797_CR31
  publication-title: Evid Based Complement Alternat Med
  doi: 10.1155/2022/9910049
SSID ssj0017874
Score 2.653153
SecondaryResourceType review_article
Snippet Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality of...
Abstract Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 94
SubjectTerms Antibodies
Antigens
Biocompatibility
Cancer
Cancer therapies
Chemotherapy
Comparative analysis
Cytokines
Drug delivery
Drug therapy
Drugs
Efficiency
Hydrogel nanoparticles
Hydrogels
Immune response
Immune system
Immunosuppressive agents
Immunotherapy
Lipid nanoparticles
Liposomes
Lymphocytes
Medical research
Metastasis
Nanomaterials
Nanoparticles
Nanotechnology
Permeability
Poly lactic-co-glycolic acid
Polymers
Radiation therapy
Review
T cell receptors
Tumor immunotherapy
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxUxEA9SULyIrV-rVSIIHmTpZjdf21stliLUk4XeQj7xge4rffsO_e-dyWYfbxH04nWTwGbym8wMmfkNIR8cd97rEOtG2Kbm0sXaWQeK17YhBeshCsHa4atv8vKaf70RN3utvjAnbKIHngR3YgGBTeJMO5t4sFwjQbhj0ccew_VcRw42bw6myvsBwJDPJTJanmzAqnF8r8TcIdWrul-YoczW_-edvGeUlgmTexbo4il5UlxHejb98iF5EIcj8nBqJnl_RB5dlWfyZ-Qc7sw1uKITuuhqoOP21_qOrrAYpJRc3Z9S8KjpZpy5IqgdAvVzb5XNc3J98eX7-WVduiXUXkg-1ixEYQOzTXAebrEk2xid87GVEFFoaZvGSxW9iCLFTimVOhGE9F0veslSct0LcjCsh_iKUKY6x0BgzPHAYxB9ECGwPkQZ4WSbVBE2C8_4QiWOHS1-mhxSaGkmgRsQuMkCN31FPu3W3E5EGn-d_RnPZDcTSbDzB4CGKdAw_4JGRT7iiRpUVfg9b0vFAWwSSa_MmRIt9jMUTUWOFzNBxfxyeMaEKSq-MRCrKrQ3HIbf74ZxJaatDXG9zXOERoIkXZGXE4R2W-pUh_R6siJ6Aa7Fnpcjw-pHJgAHpxDC1k68_h9SekMet1kxkI_ymByMd9v4Fhyt0b3LOvUbegkkig
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Na9VAEB-0ovQiWr-iVSIIHiQ0m-xH4kVqsRShniy827Jf0Qc1qS95h_73nUk2zwah1-wsZGfnc3fnNwAfLLfOVT5kuTB5xqUNmTUWFa8ofOONwyyEaofPf8izC_59JVbxwK2Pzypnmzgaat85OiM_wtRAkXrz_MvV34y6RtHtamyhcR8eEHQZSbVa7RIuhsLI50KZSh716Ns43VrSCyJVq6xeOKMRs_9_y3zLNS2fTd7yQ6dP4HEMINPjacefwr3QHsDDqaXk9QE8Oo-X5c_gBC1nhwHpJGPpuk2H7Z9uk66pJCQWXl1_TjGuTvthRoxITetTN3dY6Z_Dxem3nydnWeyZkDkh-ZAxH4TxzOTeOrRljSxCsNaFQmJeUUmT506q4EQQTSiVUk0pvJCuROZJ1jS2fAF7bdeGV5AyVVqGDGOWex68qL3wntU-yID7mzcJsJl52kVAceprcanHxKKSemK4RobrkeG6TuDTbs7VBKdxJ_VX2pMdJUFhjx-6zS8dNUsbNFF5w1llTcO94RUhyFsWXKjpPEcl8JF2VJPC4u85E-sOcJEEfaWPlSioq6HIEzhcUKKiueXwLBM6Knqv_4llAu93wzSTHq-1oduONKIimKQqgZeTCO2WVKqSQPZkAtVCuBZrXo60698jDDiGhpi8luL13f_1BvaLUeQJb_IQ9obNNrzFQGqw70ZtuQFhVBxg
  priority: 102
  providerName: ProQuest
Title Nanomaterials in tumor immunotherapy: new strategies and challenges
URI https://www.ncbi.nlm.nih.gov/pubmed/37312116
https://www.proquest.com/docview/2827111140
https://www.proquest.com/docview/2825809728
https://pubmed.ncbi.nlm.nih.gov/PMC10262535
https://doaj.org/article/a3010f418baf4da484610b1ece939017
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ra9RAEB_6wNIvovUVrUcEwQ8SzWMfiSDSlpYiXBHx4L4t-4oe1ETvcuD9987kcTZY_ZrdDdnZ3-zMZHd-A_DSMGNt7nwUcx1HTBgfGW1Q8dLUlU5bjEIod3h6JS5n7OOcz3dgKHfUC3B1a2hH9aRmy-s3v35uPqDCv28VPhdvV2izGJ1G0s0gWcio2IV9tEySKhpM2Z9TBQQnGxJnbh13CAeZzIj1TIzsVEvn__emfcNqjW9U3jBRF_fgbu9bhicdGO7Djq-O4E5XbXJzBAfT_hz9AZzhplqjr9rBL1xUYbP-Xi_DBWWL9DlZm3chutzhqhnIJEJdudAOxVdWD2F2cf7l7DLqyylElgvWRInzXLtEx85Y3OZKkXpvjPWpwJAjFzqOrZDecs9Ln0kpy4w7LmxW8EIkZWmyR7BX1ZV_AmEiM5Og7BLDHPOOF447lxTOC49LH5cBJIPwlO25xqnkxbVqY45cqE72CmWvWtmrIoDX2zE_OqaN__Y-pTXZ9iSW7PZBvfyqeqVTGnevuGRJbnTJnGY5kcubxFtf0K8eGcArWlFF6MLPs7pPScBJEiuWOpE8pYKHPA7geNQTddCOmwdMqAHCCoNZSQaJYfOLbTONpHttla_XbR-eE4NSHsDjDkLbKQ1IDCAfgWs053FLtfjWMoSj14hxbcaf_vOlz-AwbYFPLJTHsNcs1_45uleNmcCunMsJ7J-eX336PGl_UkxaPfoNnfki6g
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3JbtRAEC2FIAgXBGEzBDASiAOy4qUXGwmhEIgmJJNTIs2t6c1kJLDDLELzU3wjVV6GWEi55TrdHrmrX23urlcArw0z1ubORzHXccSE8ZHRBhUvTV3ptMUshGqHxydidMa-TvhkA_70tTB0rbK3iY2hdrWlb-S7mBpIUm8Wf7z4FVHXKDpd7VtotLA48qvfmLLNPxx-xv19k6YHX073R1HXVSCyXLBFlDjPtUt07IxFbS9F6r0x1qcCI-9c6Di2QnrLPS99JqUsM-64sFnBC5GUpcnwf2_ATXS8MSV7crJO8BIEP-sLc3KxO0dfyuiUlG4syUJGxcD5NT0C_vcEl1zh8JrmJb93cA_udgFruNci7D5s-GobbrUtLFfbcHvcHc4_gH201DUGwC2mw2kVLpY_61k4pRKUrtBr9T7EOD6cL3qGilBXLrR9R5f5Qzi7Fmk-gs2qrvwTCBOZmQQFlhjmmHe8cNy5pHBeeMRTXAaQ9MJTtiMwpz4aP1STyORCtQJXKHDVCFwVAbxbP3PR0ndcOfsT7cl6JlFvNz_Us--q02Sl0STGJUtyo0vmNMuJsd4k3vqCvh_JAN7SjioyEPh6Vnd1DrhIotpSe5Kn1EWRxwHsDGaiYtvhcI8J1RmWufqnBgG8Wg_Tk3RZrvL1spnDc6JlygN43EJovaRMZkTqJwLIB-AarHk4Uk3PG9pxDEUxWc7406vf6yVsjU7Hx-r48OToGdxJG_gT1-UObC5mS_8cg7iFedFoTgjfrltV_wKiOFqr
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nanomaterials+in+tumor+immunotherapy%3A+new+strategies+and+challenges&rft.jtitle=Molecular+cancer&rft.au=Zhu%2C+Xudong&rft.au=Li%2C+Shenglong&rft.date=2023-06-13&rft.eissn=1476-4598&rft.volume=22&rft.issue=1&rft.spage=94&rft_id=info:doi/10.1186%2Fs12943-023-01797-9&rft_id=info%3Apmid%2F37312116&rft.externalDocID=37312116
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon